NCT04037176 - Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2022

Conditions

Food Allergy

Interventions

DRUG

Omalizumab

Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE

OTHER

Placebo

Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE

Trial Locations (1)

Odense Research Center for Anaphylaxis, Allergy Center, Odense University Hospital, Odense C